NCT02710214View on ClinicalTrials.gov

A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

April 24, 2019

Study Completion Date

April 24, 2019

Conditions
MenopauseMultiple Sclerosis
Interventions
DRUG

Tissue Selective Estrogen Complex

Once-daily dosing of Duavee for 8 weeks.

DRUG

Placebo

Once-daily dosing of placebo for 8 weeks

Trial Locations (1)

94158

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

National Multiple Sclerosis Society

OTHER

lead

University of California, San Francisco

OTHER

NCT02710214 - A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis | Biotech Hunter | Biotech Hunter